GoodRx (NASDAQ:GDRX) Given New $5.50 Price Target at Truist Financial

GoodRx (NASDAQ:GDRX) had its price target decreased by investment analysts at Truist Financial from $6.50 to $5.50 in a research note issued on Thursday,Benzinga reports. The firm currently has a “hold” rating on the stock. Truist Financial’s target price would indicate a potential upside of 24.43% from the stock’s previous close.

Other equities analysts also recently issued research reports about the company. KeyCorp cut their target price on GoodRx from $7.00 to $6.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 8th. Morgan Stanley cut their price objective on GoodRx from $7.00 to $6.00 and set an “equal weight” rating on the stock in a research report on Tuesday, December 17th. Citigroup decreased their target price on GoodRx from $7.00 to $6.25 and set a “buy” rating for the company in a research report on Friday, January 10th. Finally, Wells Fargo & Company cut their price target on shares of GoodRx from $9.00 to $8.00 and set an “overweight” rating on the stock in a report on Friday, February 28th. Four investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $7.93.

GoodRx Stock Up 2.3 %

GDRX opened at $4.42 on Thursday. GoodRx has a fifty-two week low of $3.82 and a fifty-two week high of $9.26. The company has a debt-to-equity ratio of 0.70, a current ratio of 5.48 and a quick ratio of 5.48. The company’s 50-day moving average is $4.65 and its 200 day moving average is $5.07. The firm has a market capitalization of $1.70 billion, a P/E ratio of -147.33, a PEG ratio of 2.46 and a beta of 1.25.

Institutional Trading of GoodRx

Several hedge funds and other institutional investors have recently modified their holdings of the business. Barclays PLC grew its stake in GoodRx by 1,316.1% in the 3rd quarter. Barclays PLC now owns 140,113 shares of the company’s stock valued at $973,000 after buying an additional 130,219 shares in the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of GoodRx by 5.8% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 480,123 shares of the company’s stock valued at $3,332,000 after purchasing an additional 26,262 shares during the period. IMC Chicago LLC purchased a new stake in GoodRx during the 4th quarter worth about $304,000. Franklin Resources Inc. bought a new position in GoodRx in the 3rd quarter worth about $5,675,000. Finally, KLP Kapitalforvaltning AS purchased a new position in GoodRx during the 4th quarter valued at about $358,000. Institutional investors own 63.77% of the company’s stock.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.